Maharashtra FDA cancels Johnson & Johnson's baby powder manufacturing licence

The State government agency said the company's product, Johnson's Baby Powder, may affect the skin of newborn babies

September 17, 2022 09:21 am | Updated 09:21 am IST - Mumbai

File image.

File image. | Photo Credit: Reuters

Maharashtra's Food and Drugs Administration (FDA) has cancelled the baby powder manufacturing licence of Johnson & Johnson Pvt Ltd "in the interest of public health at large." In a release issued on Friday, the State government agency said the company's product, Johnson's Baby Powder, may affect the skin of newborn babies.

Samples of the powder for babies did not conform to standard pH value during a laboratory test, the regulator said.

The release said the action was taken after Kolkata-based Central Drugs Laboratory's conclusive report that concludes "the sample does not conform to IS 5339:2004 with respect to the test for pH." According to the release, FDA had drawn samples of Johnson's Baby Powder from Pune and Nashik for quality check purposes.

The government analyst had declared the samples as "not of the standard quality" as they do not comply with IS 5339:2004 specification for skin powder for infants in the test pH, it said.

Thereafter, FDA issued a show-cause notice to Johnson and Johnson under the Drugs Cosmetics Act 1940 and Rules, besides issuing instructions to the company to recall the stock of the said product from market, said the release.

The firm "didn't accept the report" of the government analyst and challenged it in court for sending it to the Central Drugs Laboratory, it added.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.